Coronavirus Update: Novavax Vaccine Listed By WHO, Filed In Japan
Plus, Booster OK For Moderna In Japan
The WHO has granted an emergency listing to Novavax's COVID-19 vaccine, paving the way for wider use along with a new approval in the EU this week. The protein-based product has also just been filed in Japan, where Moderna's mRNA shot has been newly cleared for booster use.
You may also be interested in...
Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.
The FDA authorized Comirnaty as a booster shot for 12- to 15-year-olds, as J&J's vaccine has shown effectiveness as a booster in Omicron-dominant settings. Meanwhile, Pfizer's Paxlovid won approval in the UK, and Novavax submitted the final data for its vaccine to the FDA.
India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks.